GlassScriptPhysician profile
Stephen A Williams
NPI 1962464982
$2,465.98
in general payments reported to CMS, 2019-2025
23 companies · $687 in 2025
The $687 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $702 · 2024: $1,077 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,465.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $369.89 | 2023-2025 | Repatha, Evenity, Prolia |
| Abbvie INC. | $335.28 | 2023-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $300.21 | 2023-2025 | Breztri, Airsupra |
| Axsome Therapeutics, INC. | $210.04 | 2023-2025 | Auvelity, Sunosi |
| Novartis Pharmaceuticals Corporation | $203.43 | 2023-2025 | |
| Novo Nordisk INC | $117.62 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Paratek Pharmaceuticals, INC. | $108.80 | 2023-2025 | Nuzyra |
| Lilly USA, LLC | $97.44 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $95.54 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.10 | 2023-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $73.48 | 2023-2025 | Rexulti, Nuedexta |
| Exact Sciences Corporation | $66.83 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $63.97 | 2024-2025 | Verquvo |
| Xeris Pharmaceuticals, INC. | $54.08 | 2024-2025 | Recorlev |
| Idorsia Pharmaceuticals US INC | $54.00 | 2024 | Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $50.44 | 2023-2025 | Trelegy Ellipta |
| Collegium Pharmaceutical, INC. | $46.79 | 2023-2024 | Belbuca |
| Kowa Pharmaceuticals America, INC. | $28.03 | 2023 | Seglentis, Livalo |
| Astellas Pharma US INC | $27.86 | 2023 | Veozah |
| Dexcom, INC. | $23.30 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $17.65 | 2025 | Gemtesa |
| Shield Therapeutics INC | $16.79 | 2025 | |
| Esperion Therapeutics, INC. | $14.41 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.